European Archives - Page 323 of 1448 - European Medical Journal

Tackling Tuberculosis: The Current Landscape and Future Directions

The presentation by Guy Thwaites, Director of the Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh City, Vietnam, focused on the current state of tuberculosis…

Antibiotics with Anti-Anaerobe Activity Promote Enteric Pathobionts in ICU Patients

Infectious complications in those admitted to the ICU are a major contributor to mortality. Such nosocomial infections have been…

Dolutegravir and Lamivudine vs. Efavirenz-Based Therapy for Patients with HIV and Tuberculosis

This study evaluated the efficacy and safety of a dual therapy regimen comprising double-dose dolutegravir plus lamivudine in treating…

World-First Gonorrhoea Vaccine to Launch in England

England is set to become the first country in the world to roll out a national vaccination programme against gonorrhoea, aiming to curb record-high infection rates and growing antibiotic resistance.

Extra Scans Triple Breast Cancer Detection Rate

Abbreviated MRI and contrast-enhanced mammography are more effective than ultrasound for cancer detection in women with dense breasts.

CT Screening Finds Key Signs of Cancer in Lung Cysts

New research shows cystic lung lesions with wall thickening carry a higher cancer risk, though most grow slowly.

One in Three Diabetic Patients May Develop Delirium

Diabetes significantly raises the risk of delirium, but metformin and intranasal insulin may offer protective effects.

Penicillin Allergy Misdiagnosis Corrected Through Direct Testing

This study is especially important because existing diagnostic methods, including skin testing, have shown limited sensitivity.

Bariatric Surgery Alters Fibrinogen Profiles in MASLD

A recent study investigated how different naturally occurring fibrinogen variants relate to obesity, MASLD, and liver fibrosis severity.

ESMO Breast Cancer 2025: Taxane Chemotherapy Boosts Survival in Advanced Breast Cancer

A recent multi-centre study reveals taxane-based chemotherapy is linked to markedly better one-year survival in advanced triple-negative breast cancer with genomic instability, compared to platinum-based treatments.